1. IPR in Successful University - Industry Collaborations Company Logo Cengiz A Tarhan Managing Director UCL Business PLC

2.  UCL  Enterprise at UCL – role of UCLB  Why we collaborate  Recent examples  Summary Overview

3.  Established over 180 years ago  First university in England to  admit students of any race, class or religion,  welcome women on equal terms  teach experimental science, modern European languages, Laws…  Today – over 4000 researchers and  Ranked 5th in the QS World University rankings for 2014 and 20th in the Academic Ranking of World Universities - 2014 (3rd in Europe)  Exceptional strength in BioMedicine UCL – London’s Global University

4. “UCL ranked the leading institution in the UK as a partner for industry in the biotechnology and pharmaceutical sectors” May 2013 Overview

5. Enterprise at UCL is evolving

6. Why we collaborate with Industry  It makes sense  Best universities and best companies do  Symbiotic relationship – should be two way  Helps achieve our mission to make IMPACT But;  Pick your partners well  Protect your reputation  Remain flexible on terms  Document the arrangement  Manage the relationship

7.  Direct  Studentships – beware of IP leakage  Consultancy – IP rights defined within agreement  Contract research – usually IP vested in company  Collaborative research – complex IP negotiation  Strategic partnerships – multiple programs  Indirect  Through UCL’s spin out companies  Through our partner hospitals Examples of collaboration with Industry at UCL

8.  Overvaluing IP  Undervaluing IP  Warranties and indemnities  Access to Background IP  Licensing versus assigning  Ownership of Arising/Foreground IP  Money – costs/upfront/milestones/royalties  Termination – what happens to IP  And more! When IP is Involved

9.  Eisai – drug discovery alliance  Pfizer – collaboration on stem cell- based technology  Novozymes BioPharma – combining technology platforms  Cell Therapy Catapult – treatment for leukaemia  Novo Nordisk – mapping diabetes  Takeda – tackling muscle disorders and muscular dystrophy Recent examples of collaborative research at UCL

10. Most high tech displays and touchscreens are made of transparent conductive film which requires Indium Tin Oxide (ITO)  Costs of processing ITO are high and screens tend to be brittle – not suitable for flexible displays.  Collaboration with Linde is based on developing a solution to use Single walled carbon nanotubes (SWCN) as an alternative. Unlocking the potential of Carbon Nanotubes

11.  Researchers at UCL identified a way of purifying the SWCN’s to make them useful for new generation flexible screens. Unlocking the potential of Carbon Nanotubes

12.  Patent protection secured  Licence to Linde Group in 2011  Linde Nanomaterials formed in 2012 with manufacturing facility in San Marcos, California  SEER e- Ink launched in 2013  Potential highlighted in Touch Display Research Inc., ITO- replacement report, May 2014) estimating non ITO- transparent conducting films market is likely to be worth $8.1billion by 2021 Unlocking the potential of Carbon Nanotubes

13.  UCL is committed to Enterprise to deliver IMPACT  Engagement with Industry is crucial  IPR plays an important role  It’s a relationship with ‘ups and downs’  Successful relationship needs to be ‘managed’ Summary